Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/26192
Title: Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis
Authors: George Watt
Supachai Saisorn
Krisada Jongsakul
Yuwaporn Sakolvaree
Wanpen Chaicumpa
Armed Forces Research Institute of Medical Sciences, Thailand
Mahidol University
Chiangrai Provincial Health Office
Keywords: Medicine
Issue Date: 12-Aug-2000
Citation: Journal of Infectious Diseases. Vol.182, No.1 (2000), 371-374
Abstract: There is no consensus on the benefits of treatment with any specific anthelminthic compound on muscle-stage trichinosis. A double-blind, placebo- controlled comparison was done of 3 antiparasitic drugs during an outbreak of trichinosis in Chiangrai Province, northern Thailand. Forty-six adults were randomized to receive 10 days of oral treatment with mebendazole (200 mg twice a day), thiabendazole (25 mg/kg twice a day), fluconazole (400 mg initially, then 200 mg daily), or placebo. All patients received treatment to eradicate adult intestinal worms. Trichinella spiralis infection was proved parasitologically in 19 (41%) of 46 patient and by serodiagnosis in all cases. Significantly more patients imprOVed after treatment with mebendazole (12/12) and thiabendazole (7/7) than after treatment with placebo (6/12; P < .05) or fluconazole (6/12). Muscle tenderness resolved in more patients treated with thiabendazole and mebendazole than in those treated with placebo (P < .05). However, 30% of volunteers could not tolerate the side effects of thiabendazole. In summary, Trichinella myositis responds to thiabendazole and to mebendazole.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033930348&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/26192
ISSN: 00221899
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.